TD Asset Management Inc trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 11.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 511,268 shares of the company’s stock after selling 62,881 shares during the quarter. TD Asset Management Inc owned about 1.65% of Medpace worth $210,566,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. FORA Capital LLC purchased a new stake in shares of Medpace in the 1st quarter valued at approximately $2,222,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Medpace in the 1st quarter valued at approximately $5,179,000. Eagle Asset Management Inc. raised its stake in shares of Medpace by 155.0% in the 4th quarter. Eagle Asset Management Inc. now owns 226,435 shares of the company’s stock valued at $69,409,000 after acquiring an additional 137,632 shares during the period. Evoke Wealth LLC purchased a new stake in shares of Medpace in the 4th quarter valued at approximately $3,149,000. Finally, Norden Group LLC raised its stake in shares of Medpace by 488.0% in the 1st quarter. Norden Group LLC now owns 29,480 shares of the company’s stock valued at $11,914,000 after acquiring an additional 24,466 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.
Medpace Stock Performance
MEDP opened at $347.40 on Friday. The stock has a market capitalization of $10.76 billion, a P/E ratio of 35.41, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The business’s 50-day simple moving average is $392.23 and its 200-day simple moving average is $395.70.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on MEDP shares. Deutsche Bank Aktiengesellschaft cut their target price on shares of Medpace from $395.00 to $336.00 and set a “hold” rating on the stock in a research note on Wednesday, July 24th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, July 23rd. TD Cowen cut their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. Robert W. Baird cut their target price on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 24th. Finally, Mizuho started coverage on shares of Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $423.00.
Read Our Latest Research Report on MEDP
Medpace Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
- Five stocks we like better than Medpace
- Why is the Ex-Dividend Date Significant to Investors?
- Emerging Markets: What They Are and Why They Matter
- How to Calculate Options Profits
- Recession or Not, These 3 Stocks Are Winners
- What is Insider Trading? What You Can Learn from Insider Trading
- Why NVIDIA Is More of a Screaming Buy Than Ever
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.